Please assess the completion status of the following clinical trial:

Trial Title: Allogeneic UCB Therapy With EPO in Children With CP

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosed with cerebral palsy~* Age of ≥10 months and ≤6 years~* Mismatch in HLA-A, B, and DR ≤2, and total nucleated cell count ≥3x107/kg. If the cell count is less than given values, more than 1 unit could be used.~* Hemoglobin ≤13.6 g/dL~* Decision of participation in the study by and acquisition of informed consent from the subject's representative~* Willingness and ability to be hospitalized according to the schedule specified in the protocol and continue the study for 12 months after study entry~Exclusion Criteria:~* Current aspiration pneumonia~* Known genetic disease~* History of hypersensitivity reaction to any study drugs pertinent to the study~* History of participation in any other study with stem cell~* Prior treatment with EPO within 3 months prior to study entry~* Known coagulopathy with family history of thrombosis or medical history of recurrent thrombosis~* Patient with severe seizure disease who has clinical convulsion despite combination therapy with 3 or more agents~* Uncontrolled hypertension defined as systolic blood pressure \>115 mmHg and/or diastolic blood pressure \>70 mmHg~* Hepatic impairment defined as asparate aminotransferase (AST) \>55 IU/L and/or alanine aminotransferase (ALT) \>45 IU/L~* Renal impairment defined as creatinine (Cr) ≥1.2 mg/dL~* Absolute neutrophil count ≤500/dL~* Presence of diagnosed or suspected malignant tumor and/or hematologic malignancy~* Non-compliance with study visits specified in the protocol or unwillingness of care-giver due to lack of understanding of the patient

- Gender: ALL
- Minimum Age: 10 Months
- Maximum Age: 6 Years
- Healthy Volunteers: f

Study Arms:
- UCB and EPO (Type: EXPERIMENTAL): UCB + EPO + Rehabilitation
- UCB and placebo EPO (Type: ACTIVE_COMPARATOR): UCB + placebo EPO + Rehabilitation
- placebo UCB and EPO (Type: ACTIVE_COMPARATOR): placebo UCB + EPO + Rehabilitation
- placebo UCB and placebo EPO (Type: PLACEBO_COMPARATOR): placebo UCB + placebo EPO + Rehabilitation

Based on this trial design, predict the completion outcome and termination type (if applicable).